Dijkgraaf 2015.

Methods	Controlled phase I/II trial
Participants	15 participants with platinum‐resistant ovarian cancers expressing 'mutant' p53
Interventions	C1: 6 cycles of gemcitabine (n = 3) C2: 6 cycles of gemcitabine and interferon alpha‐2b 7 days before and 22 days after first cycle of gemcitabine (n = 6) C3: 6 cycles of gemcitabine and interferon alpha‐2b with p53 SLP vaccine 7 days before and 22 days after first cycle of gemcitabine (n = 6)
Outcomes	Immune response Safety Clinical response
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	High risk	Not randomised to treatment groups
Allocation concealment (selection bias)	High risk	Sequencial allocation to treatment groups
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Information insufficient to permit judgement of ‘low risk’ or ‘high risk’
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Information insufficient to permit judgement of ‘low risk’ or ‘high risk’
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Information insufficient to permit judgement of ‘low risk’ or ‘high risk’
Selective reporting (reporting bias)	Unclear risk	Information insufficient to permit judgement of ‘low risk’ or ‘high risk’
Other bias	Low risk	No other sources of bias detected